Cargando…

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

Using laser-captured microdissection and a real-time RT–PCR assay, we quantitatively evaluated mRNA levels of the following biomarkers in paraffin-embedded gastric cancer (GC) specimens obtained by surgical resection or biopsy: excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsubara, J, Nishina, T, Yamada, Y, Moriwaki, T, Shimoda, T, Kajiwara, T, Nakajima, T E, Kato, K, Hamaguchi, T, Shimada, Y, Okayama, Y, Oka, T, Shirao, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2259181/ https://www.ncbi.nlm.nih.gov/pubmed/18231104 http://dx.doi.org/10.1038/sj.bjc.6604211

Ejemplares similares

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
por: Horiguchi, J, et al.
Publicado: (2002)

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen
por: Wei, J, et al.
Publicado: (2008)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022)

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

A ferredoxin-dependent dihydropyrimidine dehydrogenase in Clostridium chromiireducens
por: Wang, Feifei, et al.
Publicado: (2020)

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
por: Kang, Jihyun, et al.
Publicado: (2021)

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023)

Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer
por: Tominaga, Tetsuro, et al.
Publicado: (2016)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines
por: Nobuhara, Y, et al.
Publicado: (2005)

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity
por: Nagaharu, Keiki, et al.
Publicado: (2016)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
por: Diasio, Robert B., et al.
Publicado: (2022)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

A pilot study using immunohistochemical staining to characterize dihydropyrimidine dehydrogenase expression in keratinocyte neoplasms
por: Ikediobi, Ogechi, et al.
Publicado: (2023)

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine
por: Uchida, Kazumi, et al.
Publicado: (2008)

Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma
por: Hotta, K, et al.
Publicado: (2011)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

An incidental case of dihydropyrimidine dehydrogenase deficiency: One case, multiple challenges
por: Al Khallaf, Hamoud H., et al.
Publicado: (2013)

Dihydropyrimidine dehydrogenase predicts survival and response to interferon-α in hepatocellular carcinoma
por: Zhu, Wei-Ping, et al.
Publicado: (2018)

Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
por: Palmirotta, Raffaele, et al.
Publicado: (2019)

Dihydropyrimidine dehydrogenase deficiency as a cause of fatal 5-Fluorouracil toxicity
por: Fidai, Shiraz S., et al.
Publicado: (2018)

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019)

Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review
por: Hagiwara, Yuya, et al.
Publicado: (2022)

Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer
por: Joo, Jungnam, et al.
Publicado: (2016)

Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer
por: Michikawa, C, et al.
Publicado: (2011)

Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer
por: Yagi, H, et al.
Publicado: (2005)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
por: Jensen, Søren A, et al.
Publicado: (2009)

Screening of Dihydropyrimidine Dehydrogenase Genetic Variants by Direct Sequencing in Different Ethnic Groups
por: Shin, Joong-Gon, et al.
Publicado: (2013)

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
por: Patil, Vijay M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kiea7t28412r91tjacac0vhf0h